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Abstract. Regular aspirin intake is associated with a reduction
in the incidence of colorectal cancer. Aspirin has been shown
to be cytotoxic to colorectal cancer cells in vitro. The mole-
cular basis for this cytotoxicity is controversial, with a number
of competing hypotheses in circulation. One suggestion is
that the protective effect is related to the induction of expres-
sion of the DNA mismatch repair (MMR) proteins hMLH1,
hMSH2, hMSH6 and hPMS2 in DNA MMR proficient cells.
We report that treatment of the DNA MMR competent/p53
mutant colorectal cancer cell line SW480 with 1 mM aspirin
for 48 h caused changes in mRNA expression of several key
genes involved in DNA damage signalling pathways, including
a significant down-regulation in transcription of the genes
ATR, BRCA1 and MAPK12. Increases in the transcription of
XRCC3 and GADD45· genes are also reported. Regulation of
these genes could potentially have profound effects on colo-
rectal cancer cells and may play a role in the observed chemo-
protective effect of aspirin in vivo. Although a correlation
was not seen between transcript and protein levels of ATR,
BRCA1 and GADD45·, an increase in XRCC3 encoded protein
expression upon aspirin treatment in SW480 cells was observed
by immunoblotting, immunofluorescence and immunohisto-
chemical analysis. This is the first report of XRCC3 gene
transcription and encoded protein expression being suscep-
tible to exposure to the non-steroidal anti-inflammatory drug,
aspirin. Furthermore, this study indicates that alterations in
gene transcription seen in microarray studies must be verified
at the protein level.
Introduction
More than 940,000 colorectal cancer cases occur annually
worldwide whilst approximately half a million patients die
each year (1). There is abundant evidence that regular ingestion
of non-steroidal anti-inflammatory drugs (NSAIDs), such as
aspirin, can promote colorectal tumour regression and reduce
the relative risk of developing colorectal cancer (2-6). There
is also substantive evidence that aspirin is specifically cyto-
toxic against colorectal cancer cells cultured in vitro (7) and
in animal models aspirin can inhibit cancers induced by
carcinogens such as 1,2-dimethylhydrazine (8 and refs.
therein).
The molecular basis for the anti-proliferative effect of
NSAIDS, including aspirin, on colorectal cancer cells is
controversial [reviewed in ref. (9)], with a range of theories
in circulation such as; cyclooxygenase (COX) inhibition
(7,10), NF-κB inhibition (11-13), NF-κB activation (14,15),
down-regulation of Bcl-2 expression (16,17), thus making
the cells less resistant to the initiation of apoptosis, and
down-regulation of c-Myc, cyclin D1, cyclin A and proli-
ferating cell nuclear antigen (PCNA) (18), the intrinsic anti-
oxidant activity of aspirin preventing double stranded DNA
breaks (19), aspirin induces translocation of Bax to mito-
chondria (20), NSAIDSs up-regulate 15-lipoxygenase-1
expression (21), inhibition of cytosolic phospholipase A2
expression (22), depletion of intracellular polyamines (23),
increased Rac 1 expression (24), increased NSAID-activated
gene (NAG-1) protein (25 and refs. therein), selection for
microsatellite stability (26), and induction of the DNA mis-
match repair (MMR) proteins hMLH1, hMSH2, hMSH6 and
hPMS2 in DNA MMR proficient cells, which ultimately
facilitates programmed cell death (27). Identifying and under-
standing pathway modulation by aspirin is possibly key to
understanding its chemopreventative effect on colorectal
cancer.
Microarray analysis has been extensively utilised to
examine alterations in gene transcription in response to
NSAID exposure in a number of colon cancer cell lines with
a subsequent large list of alterations in gene expression
reported (24,28-31). This study aimed to investigate the
relationship between aspirin and DNA repair genes, utilising
a commercially available PCR array to analyse the expression
of 84 different genes involved in DNA damage signalling
pathways in the colorectal cancer cell line SW480 upon
aspirin treatment. We report that XRCC3 gene and protein
expression is up-regulated in SW480 cells as a consequence
of exposure to physiologically achievable levels of aspirin.
Whilst BRCA1 and ATR were noted to be significantly down-
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regulated at the mRNA level, there was no overt down-
regulation of protein expression. We also show in concordance
with previous reports (29,32) that GADD45· is induced at
the mRNA level by cultured cells exposed to a NSAID.
Materials and methods
Cell culture and treatment. All materials were purchased
from Sigma-Aldrich Co. Ltd. (Dorset, UK) unless otherwise
stated. The human colon cancer cell line SW480 (MMR-
proficient) was obtained from the European Collection of
Cell Culture (ECACC, Health Protection Agency, Wiltshire,
UK). Cells were cultured in vitro in 75 cm2 culture flasks in
L-15 Leibovitz medium supplemented with 10% Fetal Calf
Serum (PAA Laboratories Ltd., Somerset, UK) and 1%
(w/v) antibiotic solution [L-glutamine-penicillin-streptomycin
solution (stabilised antibiotic solution)] and maintained at
37˚C.
For experimental treatments, aspirin was dissolved in 1 M
Tris-HCl (pH 7.5) to a stock concentration of 0.5 M and pH
adjusted to 7.2 with 4 M HCl [as described previously in (27)].
Cell viability. The effect of aspirin on cellular viability was
measured by the 3-(4,5-dimethylthazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) conversion assay (34). Cells
were seeded into 96-well plates (104 cells per well). After 24 h
of seeding, the cells were treated for 24, 48 and 72 h by
adding various volumes of stock to obtain final concen-
trations of 0.5, 1, 3, 5 or 10 mM of aspirin. Control cells
were treated with an equivalent volume of Tris-HCl (pH 7.2).
After treatment, the cells were incubated with MTT (0.5 mg/
ml) for 3 h at 37˚C. The insoluble formazan product was
solubilised with DMSO. MTT conversion was determined by
colourimetric analysis at 540 nm. Results were calculated
from the average of three separate experiments with each
experiment performed in quintuplicate and reported as the
percentage of treated cells relative to the cells treated with
medium alone.
RT2 Profiler™ PCR Array. For PCR array analysis, the com-
mercially available Human DNA Damage Signaling Path-
ways RT2 Profiler™ Array (SuperArray Biosciences Corp.,
Frederick, MD) of 84 genes related to the DNA damage
signalling pathway was utilised. Five reference genes (B2M,
HPRT1, RPL13A, GAPDH, ACTB), RNA quality control,
reverse transcription and PCR efficiency controls are included
on the 96-well plate of the array.
At ~60% confluency, cells were treated with 1 mM aspirin
and incubated at 37˚C for 48 h. Control cells were treated
with an equivalent volume of Tris-HCl (pH 7.2). After 48 h
flasks were washed with ice cold 1X PBS and total RNA
was extracted using RNAqueous-4PCR kit for isolation of
DNA-free RNA utilising DNase I treatment (Ambion,
Austin, TX). Total RNA concentration was then quantified
using a Pharmacia GeneQuant II spectrophotometer.
Total RNA (500 ng) was reverse transcribed using 1st
strand cDNA synthesis kit for RT-PCR (AMV) (Roche,
Hertfordshire, UK). Resulting cDNA was diluted 1 in 10 in
nuclease-free water and added to SYBR Green Fluorescein
Master Mix (PrimerDesign, Southampton, UK) which was
subsequently aliquoted to each well of the PCR array for
quantitative PCR. Thermal cycling and fluorescence detection
were performed using a Biorad iCycler (Bio-Rad Laboratories,
UK). The amplification process was as per the SA Biosciences
protocol; briefly, the PCR conditions were 10 min denatu-
ration at 95˚C followed by 40 cycles of 15 sec at 95˚C and
1 min at 60˚C with melt curve analysis carried out with the
following parameters: 1 min at 95˚C followed by 1 min at
55˚C, followed by 80 cycles of 10 sec at 55˚C with an increase
in temperature after the second cycle by 0.5˚C. Five untreated
samples and five treated samples were run on individual plates
and data were analyzed with the Excel-based PCR Array Data
Analysis Template downloaded from the SuperArray website
(www.sabiosciences.com) and normalised to the expression
level of housekeeping control genes provided on the arrays.
Immunoblot analysis. For protein extraction, cells (untreated
or treated with 1 mM aspirin) were repeatedly washed with
PBS, then for GADD45· and XRCC3 protein analysis, protein
was extracted using protein extraction buffer (20 mM Tris/
150 mM NaCl/1 mM EDTA/1% Triton X) on ice for 1 h, and
centrifuged at 13000 g to remove cell fragments. Protein was
quantified using Bio-Rad's DC Protein Assay as per manu-
facturer's instructions. Extracted cellular proteins were then
dissolved in 2X Laemmli sample buffer, and analysed by
discontinuous 12% SDS-PAGE, transferred to membrane and
probed for protein expression. For XRCC3 and GADD45·
gels, resolved proteins were transferred onto nitrocellulose
membrane (Bio-Rad) at 100 v for 1 h by wet-transfer by
standard protocol (Bio-Rad Laboratories). The nitrocellulose
was blocked with 5% (w/v) non-fat milk/0.2% (v/v) Tween-20
in TBS for 60 min at room temperature and incubated with
primary antibody overnight at 4˚C, prior to repeated rinsing
with 0.2% (v/v) Tween-20 in TBS, then incubated with a
secondary HRP conjugated antibody for 60 min at room
temperature, repeatedly rinsed with 0.2% (v/v) Tween-20 in
PBS and visualised using ECL reagent according to manu-
facturer's instructions with a STORM Phosphorimager (GE
Healthcare UK Limited, Buckinghamshire, UK).
For BRCA1 and ATR protein analysis, samples were
extracted using RIPA buffer [10% NP-40 (v/v)/10% Na-
deoxycholate (v/v)/100 mM EDTA in Tris buffer pH 7.4
including Protease inhibitor cocktail tablet (Roche), Phos-
phatase inhibitor cocktail 1, Phosphatase inhibitor cocktail 2
and 200 mM PMSF]. Cell pellets were thawed on ice, re-
suspended in 3 bed volumes of extraction buffer and incu-
bated on ice for 20 min. Whole cell extracts were obtained by
centrifuging samples at 13000 rcf at 4˚C for 15 min and
samples were quantified using BCA Protein Assay kit (Pierce,
Rockford, IL, USA). Protein samples were analysed using
pre-cast 3-8% Tris-Acetate gels (Invitrogen, Paisley, UK).
Resolved proteins were transferred onto PVDF membrane
(which had been equilibrated in 100% methanol and then
equilibrated in Transfer buffer for 15 min prior to transfer) at
350 mA for 1 h. Before blocking, PVDF membrane was re-
hydrated in 100% methanol and washed briefly in PBS. The
membrane was soaked in blocking buffer [4% (w/v) Marvel™
in PBS] for 1 h at room temperature and incubated with
primary antibody (diluted in blocking buffer) overnight at 4˚C.
The membrane was then washed 3 times in wash solution
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[0.1% (v/v) Tween-20 in PBS] for 5 min each time and
incubated with secondary antibody [diluted in 5% (w/v)
Marvel™/0.1% (v/v) Tween-20 in TBS] for 1 h at room
temperature. The membrane was again washed 3 times
using wash solution for 5 min each time and then incubated
with Western Lightning™ Plus-ECL oxidising reagent plus,
enhanced Luminol reagent plus (Perkin-Elmer Life Sciences).
The membrane was then analysed using Intelligent Dark box,
LAS-3000 (Fujifilm) and Image Reader, LAS-3000 with an
exposure time of 20 min.
Samples were quantified to ensure equal concentrations
of samples were loaded for comparison studies (20 μg total
protein). To illustrate equal band loading samples were probed
for ß-tubulin protein expression using a monoclonal anti-ß-
tubulin antibody (Sigma) or monoclonal anti-·-tubulin anti-
body (Abcam, Cambridge, UK).
The primary antibodies used for immunoblotting analysis
were anti-XRCC3 antibody (1:5000 dilution; Abcam), anti-
BRCA1 antibody (1:1000; Cell Signalling Technology), anti-
ATR antibody (1:100; Cell Signalling Technology) and anti-
GADD45· antibody (1:250; Santa Cruz Biotechnology).
Immunofluorescence analysis. For immunofluorescence
analysis, briefly, cells were fixed using a methanol/acetone
mixture, washed and blocked with 5% BSA (w/v)/0.2% (v/v)
Tween-20 in PBS then repeatedly washed with 0.2% (v/v)
Tween-20 in PBS, and incubated with primary antibody at
room temperature for 60 min. Cells were again washed
with 0.2% (v/v) Tween-20 in PBS prior to incubation with
the secondary antibody and incubated for 60 min at room
temperature. Cells were washed with 0.2% (v/v) Tween-20 in
PBS, then transferred to a glass slide whereupon they were
analysed using a Carl Zeiss LSM 510 Meta confocal micro-
scope. Primary antibodies used were the same as for immuno-
blotting analysis. Secondary antibodies used were donkey
anti-rabbit IgG-FITC and donkey anti-mouse IgG-Texas Red
(both Santa Cruz Biotechnology).
Immunohistochemical analysis and analytical digital
photomicroscopy (ADP). For immunohistochemical analysis,
briefly, cells were fixed using a methanol/acetone mixture,
washed and blocked with 5% BSA (w/v)/0.2% (v/v) Tween-20
in PBS then repeatedly washed with 0.2% (v/v) Tween-20
in PBS, and incubated with anti-XRCC3 antibody (1:5000
dilution, Abcam), at room temperature for 60 min. Cells were
again washed with 0.2% (v/v) Tween-20 in PBS prior to
incubation with the anti-rabbit-HRP conjugated secondary
antibody (1:1000 dilution, Oncogene Research Products)
and incubated for 60 min at room temperature. Cells were
washed with 0.2% (v/v) Tween-20 in PBS, then incubated
with 1-Step™ TMB substrate (Pierce) for 4 min before the
reaction was stopped with ultra-pure water. The coverslips
were then mounted onto slides with mounting medium (Dako,
CA, USA). Images were obtained using a Nikon Eclipse TS100
inverted microscope and Nikon DS-Fi1 camera head and
subsequently analysed using analytical digital photomicro-
scopy (ADP) as outlined by Biocolor Ltd., UK (www.biocolor.
co.uk). Briefly, the digitally acquired images were posterized
using Adobe® Photoshop® software: blue pixels (as the
substrate conversion resulted in a subtle blue stain) were
counted in each image and recorded to give semi-quantitative
values for comparison analysis. All photographs were taken
at a constant magnification and all fields of view were of
similar confluence. Three photographs were taken of each
slide to obtain an average pixel value.
Statistical analysis. Graphical representations of changes in
cell viability were calculated using GraphPad Prism 5 software
(GraphPad Software, Inc., CA, USA). For each set of experi-
ments, where ‘n’, is stated; ‘n’ refers to individual experiments,
each run in quintuplicate. All graphs are displayed as means ±
SEM.
Results
Microarray analyses of colorectal cells exposed to non-
steroidal anti-inflammatory drugs (such as aspirin) consistently
point to an altered and increased expression of the GADD45·
gene. With respect to alterations to expression of other DNA
repair genes, Hardwick et al reported that 5 mM aspirin can
induce a 2.5-fold induction of DNA-damage-inducible trans-
cript 3 (24), whilst Iizaka et al reported that uracil DNA glyco-
sylase and XRCC5 were down-regulated by sulindac in SW480
and SW948 colorectal cancer cells (29). In light of the likely
long-term nature of aspirin treatment as a chemoprotective
agent, we reasoned that it would be informative with respect
to understanding the effect of the use of aspirin on colorectal
cell genome stability to re-examine DNA repair gene expres-
sion, using a dedicated PCR array, and exposing cells to
‘physiological’ levels (1 mM) of aspirin. We utilised the
well-studied SW480 colorectal cell line, which is DNA
mismatch repair competent but is compromised for the APC
‘gatekeeper’ and p53 ‘guardian’ genes and does not express
cyclooxygenase-2 (COX-2) (35), as a reasonable in vitro sur-
rogate for colorectal cancer.
Aspirin reduces cell viability at physiological levels. The
effect of clinically relevant concentrations of aspirin on the
SW480 cell line are shown in Fig. 1 as assessed in the MTT
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Figure 1. Cell viability analysis of SW480 cells when treated with aspirin
for 48 h. Forty-eight hour incubation with 1 mM aspirin caused significant
decreases in SW480 cell viability as assessed by MTT assay. Graphical
representations of changes in cell viability were calculated using GraphPad
Prism 5 software. All graphs are displayed as means ± SEM from 3 experi-
ments performed in quintuplicate. **P<0.05 and ***P<0.005 (One-way
ANOVA with Tukey's multiple comparison test). In control experiments,
cells were treated with equivalent levels of Tris buffer to determine toxicity
associated with carrier molecule used.
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viability assay. As noted by a number of other researchers
(7,31), we find that aspirin can exhibit a dose-dependent
inhibition of proliferation of colorectal cell lines. We have
also shown that low levels of aspirin are more toxic to colo-
rectal cancer cells than other cancer types such as glioma
(U373MG) and breast cancer (MCF-7, MDA-231-MB) cells
(data not shown). We were particularly interested in the
effect of aspirin at relatively low levels (~1 mM) in com-
parison to other studies where microarray analysis has been
utilised [see for example (30,31)], because we wished to
ensure that the results obtained were as physiologically
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Table I. Comparison of the transcriptional level of 84 genes
important for DNA damage signalling pathways analysed by
RT2 Profiler™ PCR Array.
–––––––––––––––––––––––––––––––––––––––––––––––––
Accession Gene T-test Fold difference
no. name P-value (treated/untreated)
–––––––––––––––––––––––––––––––––––––––––––––––––
Hs. 431048 ABL1 0.14 3.03
Hs.601206 ANKRD17 0.16 0.30
Hs.73722 APEX1 0.42 0.73
Hs.367437 ATM 0.46 0.59
Hs.271791 ATR 0.001 0.24
Hs.533526 ATRX 0.83 1.29
Hs.194143 BRCA1 0.04 0.15
Hs.519162 BTG2 0.46 1.84
Hs.292524 CCNH 0.08 0.09
Hs.184298 CDK7 0.34 0.63
Hs.24529 CHEK1 0.19 0.52
Hs.291363 CHEK2 0.40 0.57
Hs.135471 CIB1 0.54 1.28
Hs.249149 CIDEA 0.48 0.48
Hs.151573 CRY1 0.10 0.42
Hs.290758 DDB1 0.37 0.72
Hs.505777 DDIT3 0.71 0.83
Hs.339396 DMC1 0.74 0.81
Hs.435981 ERCC1 0.74 0.82
Hs.487294 ERCC2 0.21 1.79
Hs.498248 EXO1 0.34 0.70
Hs.591084 FANCG 0.26 6.45
Hs.409065 FEN1 0.08 0.48
Hs.292493 G22P1 0.41 0.40
Hs.80409 GADD45· 0.16 14.78
Hs.9701 GADD45Á 0.77 0.75
Hs.545196 GML 0.17 0.19
Hs.577202 GTF2H1 0.84 1.09
Hs.191356 GTF2H2 0.62 0.67
Hs.386189 GTSE1 0.83 1.22
Hs.152983 HUS1 0.63 0.64
Hs.503048 IGHMBP2 0.23 0.45
Hs.17253 IHPK3 0.62 0.38
Hs.61188 KUB3 0.60 0.79
Hs.1770 LIG1 0.17 0.55
Hs.463978 MAP2K6 0.98 0.99
Hs.432642 MAPK12 0.05 0.41
Hs.35947 MBD4 0.18 0.52
Hs.195364 MLH1 0.56 0.59
Hs.436650 MLH3 0.53 0.81
Hs.509523 MNAT1 0.61 0.58
Hs.459596 MPG 0.47 0.46
Hs.192649 MRE11A 0.97 1.02
Hs.597656 MSH2 0.23 0.65
Hs.280987 MSH3 0.71 0.77
Hs.271353 MUTYH 0.84 1.22
Hs.396494 N4BP2 0.71 0.63
Hs.492208 NBS1 0.22 8.14
Hs.66196 NTHL1 0.39 1.77
Hs.380271 OGG1 0.63 0.79
Hs.20930 PCBP4 0.11 0.21
Table I. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––
Accession Gene T-test Fold difference
no. name P-value (treated/untreated)
–––––––––––––––––––––––––––––––––––––––––––––––––
Hs.147433 PCNA 0.28 0.64
Hs.424932 PDCD8 0.71 0.80
Hs.111749 PMS1 0.49 1.58
Hs.632637 PMS2 0.11 0.66
Hs.225784 PMS2L3 0.69 0.86
Hs.78016 PNKP 0.60 1.97
Hs.631593 PPP1R15A 0.33 0.40
Hs.491682 PRKDC 0.86 1.16
Hs.531879 RAD1 0.86 1.10
Hs.16184 RAD17 0.65 1.30
Hs.375684 RAD18 0.87 1.21
Hs.81848 RAD21 0.27 0.65
Hs.128904 RAD50 0.16 9.79
Hs.631709 RAD51 0.83 1.42
Hs.172587 RAD51L1 0.07 0.47
Hs.240457 RAD9A 0.11 0.28
Hs.546282 RBBP8 0.94 1.03
Hs.443077 REV1L 0.84 0.84
Hs.461925 RPA1 0.89 0.95
Hs.408846 SEMA4A 0.18 9.55
Hs.591336 SESN1 0.46 2.00
Hs.211602 SMC1L1 0.22 0.55
Hs.81424 SUMO1 0.91 0.92
Hs.408312 TP53 0.17 0.57
Hs.192132 TP73 0.65 0.43
Hs.344812 TREX1 0.82 0.74
Hs.191334 UNG 0.63 0.87
Hs.591907 XPA 0.85 1.09
Hs.475538 XPC 0.86 0.94
Hs.98493 XRCC1 0.30 0.61
Hs.647093 XRCC2 0.78 1.42
Hs.592325 XRCC3 0.05 7.37
Hs.444451 ZAK 0.32 2.46
–––––––––––––––––––––––––––––––––––––––––––––––––
Data was analyzed with the Excel-based PCR Array Data Analysis
Template downloaded from the SuperArray website (www.
sabiosciences.com) and normalised to the expression level of
reference control genes provided on the arrays. Genes in bold are
those which showed a significant fold difference in gene expression
(P<0.05). GADD45· is also in bold.
–––––––––––––––––––––––––––––––––––––––––––––––––
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relevant as possible. Salicylate levels of 1 mM have been
reported to be achievable in serum in human subjects given
analgesic doses of aspirin (14,15,36). We selected a 48 h
incubation period with aspirin for the following reasons: cell
viability results (Fig. 1) indicate that 48 h treatments with 1 mM
aspirin cause a significant decrease in cell viability of SW480
cells [24 h treatment did not cause a significant decrease in
cell viability (data not shown)]. Stark et al reported that
significant nuclear translocation of NF-κB was possible in
SW480 cells at 48 h incubation at a concentration of 1 mM
(14). Fig. 1 also shows that the diluent (Tris-HCl buffer) had
no significant effect on cell viability at low concentrations.
Aspirin affects several key genes involved in DNA damage
signalling pathways. DNA mismatch repair proteins have been
shown to be affected by aspirin treatment (14) and may play
a part in the mechanism of action of aspirin. To investigate
whether aspirin affected expression of genes involved in DNA
damage signalling we utilised a commercially available PCR
array to assess the expression of 84 different genes involved
in DNA damage signalling pathways. Genes featured on the
array included those associated with the ATR/ATM signalling
network and transcriptional targets of DNA damage response.
PCR array analysis (Table I and Fig. 1) demonstrates that
48-h incubation of SW480 cells with 1 mM aspirin caused
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Figure 2. Graphical representation of Table I. Fold (up or down) alteration of gene transcription after treatment with 1 mM aspirin for 48 h compared to
untreated samples employing the RT2 Profiler™ PCR Array. Twenty seven out of 84 genes were up-regulated whilst 57 were down-regulated.
Figure 3. Immunoblot analysis demonstrating changes in XRCC3 but not ATR, BRCA1 or GADD45· protein expression upon 1 mM aspirin treatment over
a 48-h period compared with untreated samples in SW480 cells. Immunoblot analysis was used to examine alterations in expression of repair proteins in
SW480 cells exposed to aspirin previously highlighted by micorarray analysis. ß-tubulin was used as a loading control (n=3 for each treatment). Most notably,
little alteration in protein expression was seen for GADD45· but XRCC3 expression was substantially altered.
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marked decreases in mRNA expression of several key genes
involved in DNA damage signalling pathways including signi-
ficant decreases in BRCA1 (fold change = 0.15; P=0.04),
ATR (fold change = 0.24; P=0.001) and MAPK12 (fold
change = 0.41; P=0.05) and a significant increase in XRCC3
(fold change = 7.37; P=0.05). Whilst not statistically signi-
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Figure 4. Immunofluorescence analysis of repair protein expression in SW480 cells treated for 48 h with 1 mM aspirin. Scale bar, 20 μm. (A) Representative
FITC or Texas-Red images from three independent experiments are shown. Immunofluorescence analysis of SW480 cells probed with rabbit anti-ATR and
donkey anti-rabbit FITC demonstrated no change in expression of ATR protein upon treatment with 1 mM aspirin over a 48-h period compared with untreated
samples. Immunofluorescence analysis of SW480 cells probed with mouse anti-BRCA1 and donkey anti-mouse Texas-Red demonstrates no change in
expression of BRCA1 protein upon treatment with 1 mM aspirin over a 48-h period compared with untreated samples. Immunofluorescence analysis of
SW480 cells probed with rabbit anti-GADD45· and donkey anti-rabbit FITC demonstrated no change in expression of GADD45· protein upon treatment with
1 mM aspirin over a 48-h period compared with untreated samples. (B) Immunofluorescence analysis of SW480 cells probed with rabbit anti-XRCC3 and
donkey anti-rabbit FITC. For clarity, the Raw differential interference contrast microscopic (DIC) and Raw FITC (FITC channel only) image is shown
alongside the merged image. In contrast to ATR, BRCA1 and GADD45· an increase in expression of XRCC3 protein upon treatment with 1 mM aspirin over
a 48-h period compared with untreated samples was consistently noted.
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ficant, an increase in mRNA expression of GADD45· is of
key interest due to the large fold difference of expression
seen between treated and control samples (fold changes =
14.8; P=0.16).
Aspirin increases XRCC3 protein expression but does not affect
BRCA1, ATR or GADD45· protein expression. We investi-
gated expression of BRCA1, ATR, XRCC3 and GADD45·
encoded proteins by immunofluorescence and immunoblotting
to determine correlation with changes of mRNA expression.
These proteins were chosen for analysis based on P-value
significance (P<0.05) and difference in expression level
between control and treated samples (>4-fold). Whilst the
P-value for GADD45· is considered non-significant (>0.05),
the large fold change and previous experimental research
indicating an up-regulation of GADD45· (29,31) warranted
further investigation of this protein.
A strong correlation was noted for XRCC3 gene and
protein expression by immunoblotting (Fig. 3) and immuno-
fluorescence (Fig. 4B) analysis. However, as altered protein
expression is difficult to meaningfully quantify using these
techniques we additionally tested XRCC3 expression by
immunohistochemical analysis using ADP (Fig. 5). Here a
significant increase in XRCC3 protein expression was noted
upon 1 mM aspirin treatment for 48 h compared to untreated
samples. In contrast, the reduction in BRCA1 and ATR and
the increase in GADD45· mRNA signal were not accompa-
nied by a relative decrease or increase in protein levels as
analysed by immunoblotting (Fig. 3) and immunofluorescence
(Fig. 4A). A subtle redistribution of ATR was apparent in
aspirin treated cells, with fluorescence becoming more diffuse
in treated cells, possibly reflecting aspirin treatment altering
protein translocation/localization.
Discussion
The molecular basis for the specific cytotoxic activity of
aspirin (and indeed other NSAIDs) to colorectal cancer cells,
despite vigorous and long-standing investigation has resulted
in a plethora of competing hypotheses. Whilst expression
profile analysis of colorectal cancer cells in response to
aspirin or sulindac has been previously carried out (24,29,31),
to our knowledge this is the first study that has used PCR
array methodology to analyse gene expression upon aspirin
treatment. We report that when SW480 cells are exposed to
1 mM aspirin for 48 h, a significant decrease in the trans-
cription of ATR, BRCA1 and MAPK12 and a significant
increase in the transcription of XRCC3 occurs. Most trans-
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Figure 5. Analytical digital microscopic analysis of XRCC3 expression in SW480 cells exposed to aspirin. Digital images of SW480 cells untreated or treated
with 1 mM aspirin for 48 h were taken at x200 magnification. To quantify the subtle alterations in substrate development, pixel values were quantified using
analytical digital photomicroscopy. Statistical analysis of pixel number consistently indicated a significant increase (*P>0.05, using unpaired t-test) in aspirin
treated cells compared to untreated cells, showing an increase in XRCC3 protein expression upon aspirin treatment. Controls with secondary antibody only
and primary antibody only were also carried out and pixel number analysis demonstrated values lower than those of experimental slides indicating specificity
of the reaction and that the antibodies on their own did not cause any significant change to pixel number (data not shown).
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criptional changes were not significant but the overall
trend as shown in Fig. 2 was down-regulation, possibly
reflecting the toxic effect of aspirin on the transcriptional
machinery.
The down-regulation of transcription of the tumour sup-
pressor gene BRCA1 upon aspirin treatment (Table I) is of
interest as recently published data indicate that regular
NSAID and aspirin intake is associated with an increase in
breast cancer (37). However, immunoblotting and immuno-
fluorescence analysis of BRCA1 and ATR proteins (Figs. 3
and 4) did not show dramatic decreases in protein expression
in SW480 cells treated with 1 mM aspirin for 48 h and so did
not correlate with changes in mRNA expression as seen by
PCR array analysis. It is possible that the cells are able to
compensate at the protein level for the possible transcrip-
tional effects that are mediated by aspirin treatment, especially
if the transcriptional changes are rather subtle. This may
reflect alterations in mRNA stability or translation in addition
to the stability of the protein product or altered subcellular
locations, for example as shown by NF-κB (9,14).
The up-regulation of GADD45· upon aspirin treatment
seen in the present study has been previously reported
(29,31) and thus, can be interpreted to act as a positive
control validating our RT-PCR array data. However, we did
not find concordance between GADD45· gene transcription
and protein expression (Figs. 3 and 4). Conclusions drawn
from studies where only GADD45· expression at the
transcript level has been measured but not demonstrated
explicitly at the level of protein expression have to be viewed
cautiously. Notwithstanding such concerns, there is substantial
evidence of an involvement of GADD45· in the action of
non-steroidal anti-inflammatory drugs (NSAIDs): treatment
with NSAIDs resulted in the up-regulation of the cytokine
melanoma differentiation associated gene-7/interleukin-24
(IL-24) in a number of different cancer cell types which led
to an overexpression of GADD45· resulting in cell cycle
arrest (32). In addition, experiments utilising RNAi to knock
down GADD45· expression showed apoptosis to be prevented
in cells when treated with NSAIDs (32). Using microarray
analysis in prostate cancer cell lines Zerbini et al identified a
role for IL-24 as a mediator for NSAIDS in inducing growth
arrest and apoptosis (32). Intriguingly, IL-24 was previously
reported to exercise cytotoxicity through activation of the p38
MAPK pathway and concomitant coordinated overexpression
of the GADD family of genes in human melanoma cells (33).
Thoms et al have also reported the activation of p38 MAPK
pathway by aspirin in SW480 cells (38). However, we have
shown in this study that the transcript level of an isomer of
p38, MAPK12, is significantly down-regulated upon aspirin
treatment.
XRCC3 is a Rad51 paralog and is involved in homologous
recombination and the repair of DNA double strand breaks.
We have shown that XRCC3 protein expression is increased
in SW480 cells upon 1 mM aspirin treatment after 48 h
compared to untreated cells by immunoblotting, immunofluore-
scence and also immunohistochemical analysis. It is important
to note that whilst the overexpression of XRCC3 shown here
is not necessarily indicative of a direct role of XRCC3 in
aspirin-mediated cell death, this may have implications for the
sensitivity of cells to chemotherapeutic agents, particularly
in light of the ubiquitous use of aspirin in healthcare. Indeed,
overexpression of XRCC3 in the breast cancer cell line MCF7
induced cisplatin resistance (39). In contrast, depletion of
XRCC3 transcription by siRNA in MCF7 cells inhibited cell
proliferation, led to accumulation of DNA breaks and triggered
activation of the p53-dependant cell death (40). XRCC3
deficient HCT116 cells have shown increased sensitivity to
cisplatin and mitomycin C (42). Although some studies have
shown no association between polymorphisms in XRCC3 and
colorectal cancer risk (43-46) other studies have (47,48), and
in addition XRCC3 polymorphisms have also been associated
with breast and lung cancer susceptibility (41,49).
The present study highlights the importance of testing
changes in protein expression to confirm gene expression
analysis. We have shown changes in mRNA levels in DNA
repair genes and signaling pathways in response to aspirin
exposure (ATR, BRCA1, MAPK12, XRCC3 and GADD45·)
but expression of ATR, BRCA1 and GADD45· did not
correlate at a protein level. It may be that previous micro-
array research has highlighted changes in mRNA but these
changes are not relevant post-transcriptionally and therefore
make very little difference in actual disease pathogenesis
and/or in cytotoxicity. Similarly Goel et al (27) reported an
up-regulation in the expression of the DNA mismatch repair
proteins hMLH1, hMSH2, hMSH6 and hPMS2 in a
colorectal cancer cell line exposed to aspirin whilst showing
no significant alteration in transcription as assessed by
quantitative multiplex RT-PCR.
In conclusion, our results demonstrate via RT2 Profiler
Array analysis that aspirin causes a decrease in ATR, BRCA1
and MAPK12 and increases in XRCC3 and GADD45· gene
transcription. Protein expression analysis suggests that changes
in transcript levels of these genes do not necessarily correlate
with changes in protein expression. This finding has relevance
to microarray studies that solely rely on analysis of message
and thus raises the concern of the validity of such studies
that do not provide evidence of changes at a protein level.
However, XRCC3 expression is significantly up-regulated as
both transcript and protein in the SW480 cancer cell line as a
result of exposure to aspirin. Aspirin may have the capacity
to dysregulate XRCC3 expression and thus function, with
important implications for the response of host cells to chemo-
therapeutic agents. The significance and utility of this study
is further underlined by the recent finding that a metabolite
of aspirin (2,3-dihydrobenzoic acid) was capable of inducing
oxidative damage and DNA strand breaks in the PANC-1
human pancreatic cancer cell line (50).
Acknowledgements
We wish to acknowledge the help of the technical staff and
the support of the Research Institute in Healthcare Science at
the University of Wolverhampton. This study is dedicated to
W.A.O. Schimanke (1921-2008).
References
1. Boyle P and Levin B: World cancer report. World Health
Organization, Geneva, 2008.
2. Baron JA, Cole, BF, Sandler RS, et al: A randomized trial of
aspirin to prevent colorectal adenomas. N Engl J Med 348:
891-899, 2003.
DIBRA et al:  ASPIRIN AND DNA REPAIR PROTEIN EXPRESSION IN SW480 CELLS44
37-46.qxd  26/5/2010  12:15 ÌÌ  ™ÂÏ›‰·44
3. Imperiale TF: Aspirin and the prevention of colorectal cancer. N
Engl J Med 348: 879-880, 2003.
4. Sandler RS, Halabi S, Baron JA, et al: A randomized trial of
aspirin to prevent colorectal adenomas in patients with previous
colorectal cancer. N Engl J Med 348: 883-890, 2003.
5. Sansom OJ, Stark LA, Dunlop MG and Clarke AR: Suppression
of intestinal and mammary neoplasia by lifetime administration
of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice.
Cancer Res 61: 7060-7064, 2001.
6. Thun MJ, Henley SJ and Patrono C: Non-steroidal anti-
inflammatory drugs as anticancer agents: mechanistic, pharmaco-
logic and clinical issues. J Natl Cancer Inst 94: 252-266, 2002.
7. Smith ML, Hawcroft G and Hull MA: The effect of non-steroidal
anti-inflammatory drugs on human colorectal cancer cells:
evidence of different mechanisms of action. Eur J Cancer 36:
664-674, 2000.
8. Barnes CJ and Lee M: Determination of an optimal dosing
regimen for aspirin chemoprevention of 1,2-dimethylhydra-
zine-induced colon tumours in rats. Br J Cancer 79: 1646-1650,
1999.
9. Watson AJ: An overview of apoptosis and the prevention
of colorectal cancer. Crit Rev Oncol Hematol 57: 107-121,
2006.
10. Ferrandez A, Prescott S and Burt RW: COX-2 and colorectal
cancer. Curr Pharm Des 9: 2229-2251, 2003.
11. Kopp E and Ghosh S: Inhibition of NF-kappa B by sodium
salicylate and aspirin. Science 265: 956-959, 1994.
12. Yin MJ, Yamamoto Y and Gaynor RB: The anti-inflammatory
agents aspirin and salicylate inhibit the activity of I(kappa)B
kinase-beta. Nature 396: 77-80, 1998.
13. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB: Sulindac
inhibits activation of the NF-kappaB pathway. J Biol Chem 274:
27307-27314, 1999.
14. Stark LA, Din FV, Zwacka RM and Dunlop MG: Aspirin-
induced activation of the NF-κB signaling pathway: a novel
mechanism for aspirin-mediated apoptosis in colon cancer cells.
FASEB J 15: 1273-1275, 2001.
15. Stark LA, Reid K, Sansom OJ, et al: Aspirin activates the NF-κB
signalling pathway and induces apoptosis in intestinal neoplasia
in two in vivo models of human colorectal cancer. Carcinogenesis
28: 968-976, 2007.
16. Yu HG, Huang JA, Yang YN, et al: The effects of acetyl-
salicylic acid on proliferation, apoptosis and invasion of
cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest
32: 838-846, 2002.
17. Kim KM, Song JJ, An JY, Kwon YT and Lee YJ: Pretreatment
of acetylsalicylic acid promotes tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis by down-
regulating BCL-2 gene expression. J Biol Chem 280: 41047-
41056, 2005.
18. Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME,
Norgaard P and Moses HL: Salicylate-induced growth arrest is
associated with inhibition of p70s6k and down-regulation of
c-myc, cyclin D1, cyclin A and proliferating cell nuclear anti-
gen. J Biol Chem 275: 38261-38267, 2000.
19. Hsu CS and Li Y: Aspirin potently inhibits oxidative DNA
strand breaks: implications for cancer chemoprevention. Biochem
Biophys Res Commun 293: 705-709, 2002.
20. Zimmermann KC, Waterhouse NJ, Goldstein JC, Schuler M and
Green DR: Aspirin induces apoptosis through release of cyto-
chrome c from mitochondria. Neoplasia 2: 505-513, 2000.
21. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM
and Lippman SM: 15-Lipoxygenase-1 mediates non-steroidal
anti-inflammatory drug-induced apoptosis independently of
cyclooxygenase-2 in colon cancer cells. Cancer Res 60: 6846-6850,
2000.
22. Yu HG, Huang JA, Yang YN, et al: Inhibition of cytosolic
phospholipase A2 mRNA expression: a novel mechanism for
acetylsalicylic acid-mediated growth inhibition and apoptosis in
colon cancer cells. Regul Pept 114: 101-107, 2003.
23. Hughes A, Smith NI and Wallace HM: Polyamines reverse non-
steroidal anti-inflammatory drug-induced toxicity in human
colorectal cancer cells. Biochem J 374: 481-488, 2003.
24. Hardwick JC, van Santen M, van den Brink GR, van Deventer SJ
and Peppelenbosch MP: DNA array analysis of the effects of
aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis
25: 1293-1298, 2004.
25. Tesei A, Zoli W, Fabbri F, et al: NCX 4040, an NO-donating
acetylsalicylic acid derivative: efficacy and mechanisms of action
in cancer cells. Nitric Oxide 19: 225-236, 2008.
26. Ruschoff J, Dietmaier W, Bocker T, Brockhoff G, Hofstadter F
and Fishel R: Aspirin suppresses the mutator phenotype
associated with hereditary non-polyposis colorectal cancer by
genetic selection. Proc Natl Acad Sci USA 95: 11301-11306,
1998.
27. Goel A, Chang DK, Ricciardiello L, Gasche C and Boland CR:
A novel mechanism for aspirin-mediated growth inhibition of
human colon cancer cells. Clin Cancer Res 9: 383-390, 2003.
28. Huang RH, Chai J and Tarnawski AS: Identification of specific
genes and pathways involved in NSAIDs-induced apoptosis of
human colon cancer cells. World J Gastroenterol 12: 6446-6452,
2006.
29. Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M and
Nakamura Y: Expression profile analysis of colon cancer cells
in response to sulindac or aspirin. Biochem Biophys Res Commun
292: 498-512, 2002.
30. Germann A, Dihlmann S, Hergenhahn M, Doeberitz MK and
Koesters R: Expression profiling of CC531 colon carcinoma
cells reveals similar regulation of beta-catenin target genes by
both butyrate and aspirin. Int J Cancer 106: 187-197, 2003.
31. Yin H, Xu H, Zhao Y, Yang W, Cheng J and Zhou Y:
Cyclooxygenase-independent effects of aspirin on HT-29
human colon cancer cells, revealed by oligonucleotide micro-
arrays. Biotechnol Lett 28: 1263-1270, 2006.
32. Zerbini LF, Czibere A, Wang Y, et al: A novel pathway involving
melanoma differentiation associated gene-7/interleukin-24
mediates non-steroidal anti-inflammatory drug-induced
apoptosis and growth arrest of cancer cells. Cancer Res 66:
11922-11931, 2006.
33. Sarkar D, Su ZZ, Lebedeva IV, et al: mda-7 (IL-24) mediates
selective apoptosis in human melanoma cells by inducing the
coordinated overexpression of the GADD family of genes by
means of p38 MAPK. Proc Natl Acad Sci USA 99: 10054-10059,
2002.
34. Carmichael J, De Graff WG, Gazdar AF, Minna JD and
Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: assessment of chemosensitivity testing.
Cancer Res 47: 936-942, 1987.
35. Din FVN, Dunlop MG and Stark LA: Evidence for colorectal
cancer cell specificity of aspirin effects on NFκB signalling and
apoptosis. Br J Cancer 91: 381-388, 2004.
36. Dihlmann S, Siermann A and Doeberitz MVK: The non-steroidal
anti-inflammatory drugs aspirin and indomethacin attenuate beta-
catenin/TCF-4 signaling. Oncogene 20: 645-653, 2001.
37. Friis S, Thomassen L, Sorensen HT, et al: Non-steroidal anti-
inflammatory drug use and breast cancer risk: a Danish cohort
study. Eur J Cancer Prev 17: 88-96, 2008.
38. Thoms HC, Dunlop MG and Stark LA: p38-mediated
inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates
nucleolar translocation of Re1A and apoptosis in colorectal
cancer cells. Cancer Res 67: 1660-1669, 2007.
39. Xu ZY, Loignon M, Han FY, Panasci L and Aloyz R: XRCC3
induces cisplatin resistance by stimulation of Rad51-related
recombinational repair, S-phase checkpoint activation and
reduced apoptosis. J Pharmacol Exp Ther 314: 495-505,
2005.
40. Loignon M, Amrein L, Dunn M and Aloyz R: XRCC3 depletion
induces spontaneous DNA breaks and p53-dependent cell death.
Cell Cycle 6: 606-611, 2007.
41. Smith TR, Levine EA, Perrier ND, et al: DNA-repair genetic
polymorphisms and breast cancer risk. Cancer Epidemiol
Biomarkers Prev 12: 1200-1204, 2003.
42. Yoshihara T, Ishida M, Kinomura I, et al: XRCC3 deficiency
results in a defect in recombination and increased endo-
reduplication in human cells. EMBO J 23: 670-680, 2004.
43. Mort R, Mo L, McEwan C and Melton DW: Lack of involvement
of nucleotide excision repair gene polymorphisms in colorectal
cancer. Br J Cancer 89: 333-337, 2003.
44. Yeh CC, Sung FC, Tang R, Chang-Chieh CR and Hsieh L-L:
Polymorphisms of the XRCC1, XRCC3, & XPD genes, and
colorectal cancer risk: a case-control study in Taiwan. BMC
Cancer 5: 12, 2005.
45. Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE and
Hunter DJ: XRCC2 and XRCC3 polymorphisms are not
associated with risk of colorectal adenoma. Cancer Epidemiol
Biomarkers Prev 13: 1090-1091, 2004.
46. Skjelbred CF, Saebo M, Wallin H, et al: Polymorphisms of the
XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma
and carcinoma, in a Norwegian cohort: a case control study.
BMC Cancer 6: 67, 2006.
ONCOLOGY REPORTS  24:  37-46,  2010 45
37-46.qxd  26/5/2010  12:15 ÌÌ  ™ÂÏ›‰·45
47. Jin MJ, Chen K, Song L, et al: The association of the DNA
repair gene XRCC3 Thr241Met polymorphism with suscepti-
bility to colorectal cancer in a Chinese population. Cancer Genet
Cytogenet 163: 38-43, 2005.
48. Improta G, Sgambato A, Bianchino G, et al: Polymorphisms of
the DNA repair genes XRCC1 and XRCC3 and risk of lung and
colorectal cancer: a case-control study in a Southern Italian
population. Anticancer Res 28: 2941-2946, 2008.
49. Jacobsen NR, Raaschou-Nielsen O, Nexo B, Wallin H,
Overvad K, Tjonneland A and Vogel U: XRCC3 polymorphisms
and risk of lung cancer. Cancer Lett 213: 67-72, 2004.
50. Oikawa S, Kobayashi H, Tada-Oikawa S, Isono Y and
Kawanishi S: Damage to cellular and isolated DNA induced by
a metabolite of aspirin. Mutat Res 661: 93-100, 2009.
DIBRA et al:  ASPIRIN AND DNA REPAIR PROTEIN EXPRESSION IN SW480 CELLS46
37-46.qxd  26/5/2010  12:15 ÌÌ  ™ÂÏ›‰·46
